1 |
ClinicalTrials.gov (NCT01464437) AMG 151 Amgen Protocol Number 20100761. U.S. National Institutes of Health.
|
2 |
This week in therapeutics Endocrine disease. SciBX 2(37); doi:10.1038/scibx.2009.1408. Sept. 24, 2009
|
3 |
The hepatoselective glucokinase activator PF-04991532 ameliorates hyperglycemia without causing hepatic steatosis in diabetic rats. PLoS One. 2014 May 23;9(5):e97139.
|
4 |
Clinical pipeline report, company report or official report of vTv Therapeutics, NCT02405260.
|
5 |
Clinical pipeline report, company report or official report of Eli Lilly.
|
6 |
Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes. Diabetes Obes Metab. 2015 Aug;17(8):751-9.
|
7 |
Clinical pipeline report, company report or official report of AstraZeneca (2009).
|
8 |
Clinical pipeline report, company report or official report of vTv Therapeutics.
|
9 |
Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
|
10 |
Utilization of the Zucker Diabetic Fatty (ZDF) Rat Model for Investigating Hypoglycemia-related Toxicities. Toxicol Pathol. 2015 Aug;43(6):825-37.
|
11 |
Glucokinase alternative. SciBX 6(45); doi:10.1038/scibx.2013.1279. Nov. 21 2013
|
|
|
|
|
|
|